ABBV Stock Analysis: Buy, Sell, or Hold?
ABBV - ABBVIE INC.
$208.50
0.64 (0.31%)
▲
5d:
+1.69%
30d:
-0.84%
90d:
-5.61%
BUY
HIGH Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: Apr 29, 2026
0d
Smart Money Accumulation
None View Scanner →
Strength: 7.0/10
Get Alerted When ABBV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
7 traders called ABBV this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ABBV trading at deep discount. Market pricing in -3.5% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: ABBV trading at deep discount. Market pricing in -3.5% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$354.10
Based on 8.9% avg growth
INTRINSIC VALUE TODAY
$219.87
5.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ABBV is currently trading at $208.50, which is considered slightly high relative to its 30-day fair value range of $201.53 to $209.62. From a valuation perspective, the stock is trading at a discount (Forward PE: 12.9) compared to its historical average (14.3). Remarkably, the market is currently pricing in an annual earnings decline of 3.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ABBV is in a strong uptrend. Immediate support is located at $200.02, while resistance sits at $214.87.
Market Sentiment: ABBV has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $252.23 (+21.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ABBV is in a strong uptrend. Immediate support is located at $200.02, while resistance sits at $214.87.
Market Sentiment: ABBV has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $252.23 (+21.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$201.53 -
$209.62
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
76.2%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 21.0% below Wall St target ($252.23)
Trading Range Analysis
30-Day Trading Range
$201.53 -
$209.62
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$200.02
Resistance Level
$214.87
Current Trend
Strong Uptrend
Technical data as of
May 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.86
Wall Street Target
$252.23
(+21.0%)
Revenue Growth (YoY)
12.4%
Earnings Growth (YoY)
-46.2%
Profit Margin
5.8%
Valuation Discount vs History
-3.5% cheaper
PE vs Historical
12.9 vs 14.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.5%
(market-implied from PE analysis)
1-Year Target
$201.20
(-4%)
2-Year Target
$194.16
(-7%)
3-Year Target
$187.36
(-10%)
3-Yr Target (if PE normalizes)
(PE: 13→14)
$208.29
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 13.8%)
$526.15
(+152%)
Base:
(SPY PE: 12.9, Growth: 13.8%)
$307.08
(+47%)
Bear:
(PE: 10.9, Growth: 13.8%)
$261.02
(+25%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Forward PE: 14.14 | Forward EPS (Implied): $14.74
Bull Case
$251.76
(+21%)
Analyst growth 15.0%, PE expands to 14.9
Base Case
$208.50
(0%)
Market implied 0.0%, PE stable at 14.1
Bear Case
$159.50
(-24%)
Severe decline -15.0%, PE contracts to 12.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.9 to 14.3
Stabilization Target:
$231.78
(+11.2%)
PE Expansion Potential:
+11.2%
Share & Embed Analysis
Last updated: May 14, 2026 9:46 AM ET
Data refreshes hourly during market hours. Next update: 10:46 AM
Data refreshes hourly during market hours. Next update: 10:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABBV showing a specific setup today?
Insider Activity (6 Months)
2
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
SELL
2026-03-30
David Ryan Purdue
SELL
5230 shares
2026-03-04
Perry C Siatis
SELL
22381 shares
2026-02-25
Featured in Portfolios
ABBV is a key holding in these high-performance investment strategies.
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1209 | 61 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 59 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$217 | 64 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 58 HOLD |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$130 | 61 BUY |
Advanced ABBV Option Strategies
Professional options setups generated by AI based on today's ABBV price and gamma walls.
